Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceGlobeNewsWire • 04/04/24
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransProactive Investors • 04/02/24
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory BoardGlobeNewsWire • 04/02/24
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San DiegoGlobeNewsWire • 03/28/24
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's TechnologyGlobeNewsWire • 03/14/24
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”GlobeNewsWire • 03/13/24
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic InsomniaGlobeNewsWire • 03/06/24
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation DeviceGlobeNewsWire • 02/08/24
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) SystemGlobeNewsWire • 01/23/24
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant DepressionGlobeNewsWire • 12/18/23
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David LasseterGlobeNewsWire • 10/25/23
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain StructuresGlobeNewsWire • 10/16/23
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related SymptomsGlobeNewsWire • 08/07/23
Nexalin's CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern TimeGlobeNewsWire • 08/03/23
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government AgenciesGlobeNewsWire • 07/26/23
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain InjuryGlobeNewsWire • 07/10/23
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's tACS Devices in the Asia Pacific RegionGlobeNewsWire • 06/01/23
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and RegulatoryGlobeNewsWire • 01/24/23
Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety DisorderGlobeNewsWire • 11/14/22
Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public OfferingGlobeNewsWire • 09/20/22
Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public OfferingGlobeNewsWire • 09/16/22
